2-(2,2-Dimethoxy-acetyl)-6-phenethyl-cyclohexanone | 144147-84-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2,2-Dimethoxy-acetyl)-6-phenethyl-cyclohexanone
• 英文别名: 2-(2,2-Dimethoxyacetyl)-6-(2-phenylethyl)cyclohexan-1-one
• CAS: 144147-84-2
• 化学式: C₁₈H₂₄O₄
• 分子量: 304.386
• InChiKey: KQKNBNJRBSQYNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2,2-Dimethoxy-acetyl)-6-phenethyl-cyclohexanone 在 盐酸 、 manganese(IV) oxide 、 sodium acetate 、 sodium hydride 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 甲苯 、 苯 为溶剂， 反应 6.5h， 生成 (E)-7-[2-(4-Fluoro-phenyl)-7-phenethyl-4,5,6,7-tetrahydro-2H-indazol-3-yl]-5-hydroxy-3-oxo-hept-6-enoic acid ethyl ester
  参考文献：
  名称：

  HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts

  摘要：

  Compounds comprising a series of 7-[2-(4-fluorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-3,5-dihydroxy-6-heptenoic acid sodium salts (18) were synthesized and tested for their ability to inhibit HMG-CoA reductase in a partially purified enzyme preparation and cholesterol biosynthesis from acetate in cultured HEP-G2 cells. Changing the size of the saturated ring of the tetrahydroindazole nucleus did not improve potency, but incorporation of substituents at the 7-position resulted in up to 1700-fold improvement in inhibitory potency. Structure-activity studies revealed that the most potent compounds possess a substituted benzyl group at the 7-position, with a preference for steric bulk at the para position of the benzene ring. The most potent enzyme inhibitor (18t, IC50 = 3.0 nM) is approximately 3-fold more potent than lovastatin sodium salt (2). The most potent cholesterol biosynthesis inhibitor in HEP-G2 cells (18q, IC50 = 0.078 muM) is slightly less potent than 2 (sodium salt). Molecular modeling studies suggested that, when compared to the parent compound (18b) lacking the appropriate 7-substituent, 18t overlaps better with 2 and literature inhibitors 5 and 6 in a hydrophobic binding region adjacent to the enzyme active site.

  DOI：

  10.1021/jm00075a024
• 作为产物：
  描述：

  二甲氧基乙酸甲酯 、 2-苯乙基环己烷-1-酮 在 正丁基锂 、 二异丙胺 作用下， 生成 2-(2,2-Dimethoxy-acetyl)-6-phenethyl-cyclohexanone
  参考文献：
  名称：

  HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts

  摘要：

  Compounds comprising a series of 7-[2-(4-fluorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-3,5-dihydroxy-6-heptenoic acid sodium salts (18) were synthesized and tested for their ability to inhibit HMG-CoA reductase in a partially purified enzyme preparation and cholesterol biosynthesis from acetate in cultured HEP-G2 cells. Changing the size of the saturated ring of the tetrahydroindazole nucleus did not improve potency, but incorporation of substituents at the 7-position resulted in up to 1700-fold improvement in inhibitory potency. Structure-activity studies revealed that the most potent compounds possess a substituted benzyl group at the 7-position, with a preference for steric bulk at the para position of the benzene ring. The most potent enzyme inhibitor (18t, IC50 = 3.0 nM) is approximately 3-fold more potent than lovastatin sodium salt (2). The most potent cholesterol biosynthesis inhibitor in HEP-G2 cells (18q, IC50 = 0.078 muM) is slightly less potent than 2 (sodium salt). Molecular modeling studies suggested that, when compared to the parent compound (18b) lacking the appropriate 7-substituent, 18t overlaps better with 2 and literature inhibitors 5 and 6 in a hydrophobic binding region adjacent to the enzyme active site.

  DOI：

  10.1021/jm00075a024

文献信息

• Tetrahydro-indazole cannabinoid modulators
  申请人：Lagu Bharat

  公开号：US20050228034A1

  公开（公告）日：2005-10-13

  This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

  这项发明涉及一种式I的四氢吲哚类大麻素调节剂化合物，以及一种用于治疗、改善或预防大麻素受体介导的综合症、紊乱或疾病的方法。
• TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS
  申请人：Lagu Bharat

  公开号：US20090099143A1

  公开（公告）日：2009-04-16

  This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

  本发明涉及一种式为I的四氢吲哚类大麻素调节剂化合物，以及用于治疗、改善或预防大麻素受体介导的综合征、疾病或疾病的方法。
• US7452997B2
  申请人：——

  公开号：US7452997B2

  公开（公告）日：2008-11-18
• [EN] TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS<br/>[FR] MODULATEURS DES CANNABINOIDES A BASE DE TETRAHYDRO-INDAZOLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005095353A1

  公开（公告）日：2005-10-13

  This invention is direction to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.
• HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts
  作者：Peter J. Connolly、Claudia D. Westin、Deborah A. Loughney、Lisa K. Minor

  DOI：10.1021/jm00075a024

  日期：1993.11

  Compounds comprising a series of 7-[2-(4-fluorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-3,5-dihydroxy-6-heptenoic acid sodium salts (18) were synthesized and tested for their ability to inhibit HMG-CoA reductase in a partially purified enzyme preparation and cholesterol biosynthesis from acetate in cultured HEP-G2 cells. Changing the size of the saturated ring of the tetrahydroindazole nucleus did not improve potency, but incorporation of substituents at the 7-position resulted in up to 1700-fold improvement in inhibitory potency. Structure-activity studies revealed that the most potent compounds possess a substituted benzyl group at the 7-position, with a preference for steric bulk at the para position of the benzene ring. The most potent enzyme inhibitor (18t, IC50 = 3.0 nM) is approximately 3-fold more potent than lovastatin sodium salt (2). The most potent cholesterol biosynthesis inhibitor in HEP-G2 cells (18q, IC50 = 0.078 muM) is slightly less potent than 2 (sodium salt). Molecular modeling studies suggested that, when compared to the parent compound (18b) lacking the appropriate 7-substituent, 18t overlaps better with 2 and literature inhibitors 5 and 6 in a hydrophobic binding region adjacent to the enzyme active site.